Rigel Pharmaceuticals initiates Phase 3 studies of fostamatinib in ITP

Rigel Pharmaceuticals initiated a Phase 3 clinical program for its oral SYK inhibitor, fostamatinib, in patients with ITP - immune thrombocytopenic purpura. The focus of these clinical studies is to evaluate the potential of fostamatinib to increase the platelet counts of patients with chronic ITP. Fostamatinib may provide a novel therapeutic for the underlying cause of this autoimmune disease of the blood.